Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New proton beam approach targets bulky tumors

NCT ID NCT05121545

Symptom relief Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new type of proton therapy called Pro-GRID for people with large tumors (over 7 cm) that are hard to treat. The goal is to see if the treatment is safe and can shrink tumors or ease symptoms. About 11 adults with sarcoma or melanoma are taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

11 people

The number who actually took part.

Started

Apr 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 * Histologically or cytologically confirmed invasive cancer * Bulky tumor \> 7 cm, determined clinically and/or radiographically, at the time of evaluation prior to enrollment * Treated indicated for palliative intent * Eastern Cooperative Oncology Group (ECOG) performance status \< 2 * Anticipated treatment deemed safe on pre-review by PI * For patients with prior Radiation Therapy (RT): Dicoms must be available for dose fusion if overlap anticipated with GRID * Willing and able to provide informed consent * Discussion with medical oncology or surgical specialty Exclusion Criteria: * Age \< 18 * ECOG performance status 3-4 * Planned for definitive, curative management * For patients with prior RT that overlaps with Pro-GRID: Dicoms not available Pregnant women * Tumor encasing critical structure, as defined by the treating MD.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melanoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

melanoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melanoma Sarcoma

Contacts and locations

Locations

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia, 20016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.